Vivaldi Biosciences has acquired from Baxter Healthcare research and development assets, including intellectual property, clinical data, know-how and materials, for LAIVs in which the gene for influenza nonstructural protein 1 has been fully deleted.
NS1 is a multifunctional virulence factor of influenza.
In a Phase 1 clinical study of a delta-NS1 LAIV for highly pathogenic avian influenza A(H5N1) (“bird flu”), two Phase 1 studies of delta-NS1 LAIVs for seasonal H1N1 influenza strains, and a Phase 1/2 study of a trivalent delta-NS1 LAIV for seasonal influenza, the candidate vaccines were well-tolerated and generated positive immunogenicity data in a dose-dependent manner.
The vaccines evaluated in the four clinical studies were produced using Vero cell substrate technologies.
The acquired assets complement and substantially broaden Vivaldi’s LAIV platform and product development opportunities in pandemic preparedness and seasonal influenza.
For further deal information visit Current Agreements (subscription required)
Read: Big pharma deal news - latest deal news for top 50 pharma / big pharma companies
Report: Partnering Deals and Alliances with Baxter Healthcare
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity